B lymphocytes are an important cell population of the immune system. However, until recently it was not possible to transduce resting B lymphocytes with retro- or lentiviral vectors, making them unsusceptible for genetic manipulations by these vectors. Lately, we demonstrated that lentiviral vectors pseudotyped with modified measles virus (MV) glycoproteins hemagglutinin, responsible for receptor recognition, and fusion protein were able to overcome this transduction block. They use either the natural MV receptors, CD46 and signaling lymphocyte activation molecule (SLAM), for cell entry (MV-LV) or the vector particles were further modified to selectively enter via the CD20 molecule, which is exclusively expressed on B lymphocytes (CD20-LV). It has been shown previously that transduction by MV-LV does not induce B lymphocyte activation. However, if this is also true for CD20-LV is still unknown. Here, we generated a vector specific for another B lymphocyte marker, CD19, and compared its ability to transduce resting B lymphocytes with CD20-LV. The vector (CD19ds-LV) was able to stably transduce unstimulated B lymphocytes, albeit with a reduced efficiency of about 10% compared to CD20-LV, which transduced about 30% of the cells. Since CD20 as well as CD19 are closely linked to the B lymphocyte activation pathway, we investigated if engagement of CD20 or CD19 molecules by the vector particles induces activating stimuli in resting B lymphocytes. Although, activation of B lymphocytes often involves calcium influx, we did not detect elevated calcium levels. However, the activation marker CD71 was substantially up-regulated upon CD20-LV transduction and most importantly, B lymphocytes transduced with CD20-LV or CD19ds-LV entered the G1b phase of cell cycle, whereas untransduced or MV-LV transduced B lymphocytes remained in G0. Hence, CD20 and CD19 targeting vectors induce activating stimuli in resting B lymphocytes, which most likely renders them susceptible for lentiviral vector transduction.
References
[1]
Zanetti M, Castiglioni P, Rizzi M, Wheeler M, Gerloni M (2004) B lymphocytes as antigen-presenting cell-based genetic vaccines. Immunol Rev 199: 264–278.
[2]
Serafini M, Naldini L, Introna M (2004) Molecular evidence of inefficient transduction of proliferating human B lymphocytes by VSV-pseudotyped HIV-1-derived lentivectors. Virology 325: 413–424.
[3]
Korin YD, Zack JA (1998) Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol 72: 3161–3168.
[4]
Unutmaz D, KewalRamani VN, Marmon S, Littman DR (1999) Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med 189: 1735–1746.
[5]
Frecha C, Costa C, Negre D, Gauthier E, Russell SJ, et al. (2008) Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 112: 4843–4852.
[6]
Frecha C, Costa C, Levy C, Negre D, Russell SJ, et al. (2009) Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood 114: 3173–3180.
[7]
Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, et al. (2008) Targeted cell entry of lentiviral vectors. Mol Ther 16: 1427–1436.
[8]
Frecha C, Levy C, Costa C, Negre D, Amirache F, et al. (2011) Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors. J Virol 85: 5975–5985.
[9]
Zhou Q, Schneider IC, Gallet M, Kneissl S, Buchholz CJ (2011) Resting lymphocyte transduction with measles virus glycoprotein pseudotyped lentiviral vectors relies on CD46 and SLAM. Virology 413: 149–152.
[10]
Mühlebach MD, Mateo M, Sinn PL, Prüfer S, Uhlig KM, et al. (2011) Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 480: 530–533.
[11]
Noyce RS, Bondre DG, Ha MN, Lin LT, Sisson G, et al. (2011) Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog 7: e1002240.
[12]
Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, et al. (2005) Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23: 209–214.
[13]
Anliker B, Abel T, Kneissl S, Hlavaty J, Caputi A, et al. (2010) Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods 7: 929–935.
[14]
Zhou Q, Buchholz CJ (2013) Cell type specific gene delivery by lentiviral vectors: New options in immunotherapy. Oncoimmunology 2: e22566.
[15]
Münch RC, Mühlebach MD, Schaser T, Kneissl S, Jost C, et al. (2011) DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther 19: 686–693.
[16]
Zhou Q, Schneider IC, Edes I, Honegger A, Bach P, et al. (2012) T-cell receptor gene transfer exclusively to human CD8+ cells enhances tumor cell killing. Blood 120: 4334–4342.
[17]
Buchholz CJ, Mühlebach MD, Cichutek K (2009) Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer? Trends Biotechnol 27: 259–265.
Harwood NE, Batista FD (2008) New insights into the early molecular events underlying B cell activation. Immunity 28: 609–619.
[20]
Niiro H, Clark EA (2002) Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2: 945–956.
[21]
Tedder TF, Engel P (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15: 450–454.
[22]
Walshe CA, Beers SA, French RR, Chan CH, Johnson PW, et al. (2008) Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem 283: 16971–16984.
[23]
Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, et al. (2005) Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). Br J Haematol 130: 218–228.
[24]
Peipp M, Saul D, Barbin K, Bruenke J, Zunino SJ, et al. (2004) Efficient eukaryotic expression of fluorescent scFv fusion proteins directed against CD antigens for FACS applications. J Immunol Methods 285: 265–280.
[25]
Reiter Y, Brinkmann U, Kreitman RJ, Jung SH, Lee B, et al. (1994) Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry 33: 5451–5459.
[26]
Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, et al. (2002) B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 99: 4087–4093.
[27]
Pezzutto A, Dorken B, Rabinovitch PS, Ledbetter JA, Moldenhauer G, et al. (1987) CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol 138: 2793–2799.
[28]
Cragg MS, Walshe CA, Ivanov AO, Glennie MJ (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8: 140–174.
[29]
Yoder A, Yu D, Dong L, Iyer SR, Xu X, et al. (2008) HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell 134: 782–792.
[30]
Li X, Sandoval D, Freeberg L, Carter RH (1997) Role of CD19 tyrosine 391 in synergistic activation of B lymphocytes by coligation of CD19 and membrane Ig. J Immunol 158: 5649–5657.
[31]
Tuveson DA, Carter RH, Soltoff SP, Fearon DT (1993) CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science 260: 986–989.
[32]
Polyak MJ, Li H, Shariat N, Deans JP (2008) CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem 283: 18545–18552.
[33]
Li H, Ayer LM, Lytton J, Deans JP (2003) Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 278: 42427–42434.
[34]
Uchida J, Lee Y, Hasegawa M, Liang Y, Bradney A, et al. (2004) Mouse CD20 expression and function. Int Immunol 16: 119–129.
[35]
Golay JT, Clark EA, Beverley PC (1985) The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 135: 3795–3801.
[36]
Ginaldi L, De MM, Matutes E, Farahat N, Morilla R, et al. (1998) Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 51: 364–369.
[37]
Kheirallah S, Caron P, Gross E, Quillet-Mary A, Bertrand-Michel J, et al. (2010) Rituximab inhibits B-cell receptor signaling. Blood 115: 985–994.
[38]
Sloan DD, Han JY, Sandifer TK, Stewart M, Hinz AJ, et al. (2006) Inhibition of TCR signaling by herpes simplex virus. J Immunol 176: 1825–1833.
[39]
Bucheit AD, Kumar S, Grote DM, Lin Y, von Messling V, et al. (2003) An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 7: 62–72.
[40]
Fujimoto M, Poe JC, Hasegawa M, Tedder TF (2001) CD19 amplification of B lymphocyte Ca2+ responses: a role for Lyn sequestration in extinguishing negative regulation. J Biol Chem 276: 44820–44827.
[41]
Kügler M, Stein C, Schwenkert M, Saul D, Vockentanz L, et al. (2009) Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework. Protein Eng Des Sel 22: 135–147.
[42]
Kneissl S, Abel T, Rasbach A, Brynza J, Schneider-Schaulies J, et al. (2012) Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies. PLoS One 7: e46667.
[43]
Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871–875.
[44]
Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, et al. (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13: 803–813.
[45]
Itoh K, Tezuka H, Sakoda H, Konno M, Nagata K, et al. (1989) Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow. Exp Hematol 17: 145–153.
